Study Phase 3

Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial

  • PDF icon for CSR Summary CSR Summary Not Yet Available
  • Globe symbol for NCT Number NCT Number Not Available
  • Notebook for Primary Citation Primary Citation
  • Spreadsheet for Data Specification Data Specification Not Available

Trial Information

Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaNervous SystemProduct ClassPsychoanalepticsPharmacological SubgroupAnti-Dementia DrugsChemical SubgroupAnticholinesterasesCondition StudiedAlzheimer Disease
Sponsor Protocol NumberGAL-CAN-5Enrollment130Data PartnerJohnson & Johnson% FemaleN/AMean/Median Age (Years)N/A% WhiteN/A

Supporting Documentation

  • Protocol with Amendments Available
  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the protocol and full clinical study report are available.

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.